Unsolved:Osteopenia

From HandWiki
Revision as of 23:07, 4 February 2024 by AIposter (talk | contribs) (link)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Osteopenia
Other namesLow bone mass, low bone density
SpecialtyRheumatology, Endocrinology
SymptomsUsually asymptomatic
ComplicationsDevelopment into Osteoporosis
Risk factorsOld age, European or Asian ethnicity, alcoholism, smoking, low body mass index
Diagnostic methodBone density scan
PreventionAdequate Vitamin D and calcium, regular weight bearing exercise, avoiding excessive alcohol and smoking
TreatmentUsually unmerited
MedicationUsually unmerited

Osteopenia, known as "low bone mass" or "low bone density", is a condition in which bone mineral density is low.[1] Because their bones are weaker, people with osteopenia may have a higher risk of fractures, and some people may go on to develop osteoporosis.[2] In 2010, 43 million older adults in the US had osteopenia.[3] Unlike osteoporosis, osteopenia does not usually cause symptoms, and losing bone density in itself does not cause pain.

There is no single cause for osteopenia, although there are several risk factors, including modifiable (behavioral, including dietary and use of certain drugs) and non-modifiable (for instance, loss of bone mass with age). For people with risk factors, screening via a DXA scanner may help to detect the development and progression of low bone density. Prevention of low bone density may begin early in life and includes a healthy diet and weight-bearing exercise, as well as avoidance of tobacco and alcohol. The treatment of osteopenia is controversial: non-pharmaceutical treatment involves preserving existing bone mass via healthy behaviors (dietary modification, weight-bearing exercise, avoidance or cessation of smoking or heavy alcohol use). Pharmaceutical treatment for osteopenia, including bisphosphonates and other medications, may be considered in certain cases but is not without risks. Overall, treatment decisions should be guided by considering each patient's constellation of risk factors for fractures.

Osteopenia exists on a spectrum of normal to dangerously low bone density (osteoporosis).

Risk factors

Many divide risk factors for osteopenia into fixed (non-changeable) and modifiable factors. Osteopenia can also be secondary to other diseases. An incomplete list of risk factors:[4][5][6]

Bone density peaks at 35 and then decreases with age.

Fixed

  • Age: bone density peaks at age 35, and then decreases. Bone density loss occurs in both men and women[7]
  • Ethnicity: European and Asian people have increased risk[8]
  • Sex: women are at higher risk, particularly those with early menopause
  • Family history: low bone mass in the family increases risk

Modifiable / behavioral

  • Tobacco use
  • Alcohol use
  • Inactivity – particularly lack of weight-bearing or resistance activities [9][10][11]
  • Insufficient caloric intake – osteopenia can be connected to female athlete triad syndrome, which occurs in female athletes as a combination of energy deficiency, menstrual irregularities, and low bone mineral density.[12]
  • Low nutrient diet (particularly calcium, Vitamin D)

Other diseases

  • Celiac disease, via poor absorption of calcium and vitamin D[13][14]
  • Hyperthyroidism[15]
  • Anorexia nervosa[16]

Medications

  • Steroids[17]
  • Anticonvulsants

Screening and diagnosis

The ISCD (International Society for Clinical Densitometry) and the National Osteoporosis Foundation recommend that older adults (women over 65 and men over 70) and adults with risk factors for low bone mass, or previous fragility fractures, undergo DXA testing.[18] The DXA (dual X-ray absorptiometry) scan uses a form of X-ray technology, and offers accurate bone mineral density results with low radiation exposure.[19][20]

The United States Preventive Task Force recommends osteoporosis screening for women with increased risk over 65 and states there is insufficient evidence to support screening men.[21] The main purpose of screening is to prevent fractures. Of note, USPSTF screening guidelines are for osteoporosis, not specifically osteopenia.

A DXA scanner in use.

The National Osteoporosis Foundation recommends use of central (hip and spine) DXA testing for accurate measure of bone density, emphasizing that peripheral or "screening" scanners should not be used to make clinically meaningful diagnoses and that peripheral and central DXA scans cannot be compared to each other.[22]

DXA scanners can be used to diagnose osteopenia or osteoporosis as well as to measure bone density over time as people age or undergo medical treatment or lifestyle changes.[23]

Information from the DXA scanner creates a bone mineral density T-score by comparing a patient's density to the bone density of a healthy young person. Bone density between 1 and 2.5 standard deviations below the reference, or a T-score between −1.0 and −2.5, indicates osteopenia (a T-score smaller than or equal to −2.5 indicates osteoporosis). Calculation of the T-score itself may not be standardized. The ISCD recommends using Caucasian women between 20 and 29 years old as the baseline for bone density for ALL patients, but not all facilities follow this recommendation.[24][25][26][18]

The ISCD recommends that Z-scores, not T-scores, be used to classify bone density in premenopausal women and men under 50.[18]

Prevention

Prevention of low bone density can start early in life by maximizing peak bone density. Once a person loses bone density, the loss is usually irreversible, so preventing (greater than normal) bone loss is important.[27]

Actions to maximize bone density and stabilize loss include:[28][29][30][31]

  • Exercise, particularly weight-bearing exercise, resistance exercises and balance exercises, through mechanical loading that promotes increased bone mass, and reduced fall risk [32]
  • Adequate caloric intake
  • Sufficient calcium in diet: older adults may have increased calcium needs—of note, medical conditions such as Celiac and hyperthyroidism can affect absorption of calcium[29]
  • Sufficient Vitamin D in diet
  • Estrogen replacement
  • Avoidance of steroid medications
  • Limit alcohol use and smoking

Treatment

The pharmaceutical treatment of osteopenia is controversial and more nuanced than well-supported recommendations for improved nutrition and weight-bearing exercise.[33][34][6] The diagnosis of osteopenia in and of itself does not always warrant pharmaceutical treatment.[35][36] Many people with osteopenia may be advised to follow risk prevention measures (as above).

Risk of fracture guides clinical treatment decisions: the World Health Organization (WHO) Fracture Risk Assessment Tool (FRAX) estimates the probability of hip fracture and the probability of a major osteoporotic fracture (MOF), which could occur in a bone other than the hip.[37][38] In addition to bone density (T-score), calculation of the FRAX score involves age, body characteristics, health behaviors, and other medical history.[39]

As of 2014, The National Osteoporosis Foundation (NOF) recommends pharmaceutical treatment for osteopenic postmenopausal women and men over 50 with FRAX hip fracture probability of >3% or FRAX MOF probability >20%.[40] As of 2016, the American Association of Clinical Endocrinologists and the American College of Endocrinology agree.[41] In 2017, the American College of Physicians recommended that clinicians use individual judgment and knowledge of patients' particular risk factors for fractures, as well as patient preferences, to decide whether to pursue pharmaceutical treatment for women with osteopenia over 65.[42]

Pharmaceutical treatment for low bone density includes a range of medications. Commonly used drugs include bisphosphonates (alendronate, risedronate, and ibandronate)—some studies show that decreased fracture risk and increased bone density after bisphosphonate treatment for osteopenia.[43] Other medications include selective estrogen receptor modulators (SERMs) (e.g., raloxifene), estrogens (e.g., estradiol), calcitonin, and parathyroid hormone-related protein analogues (e.g., abaloparatide, teriparatide).[44]

These drugs are not without risks.[45][46] In this complex landscape, many argue that clinicians must consider a patient's individual risk of fracture, not simply treat those with osteopenia as equally at risk. A 2005 editorial in the Annals of Internal Medicine states "The objective of using osteoporosis drugs is to prevent fractures. This can be accomplished only by treating patients who are likely to have a fracture, not by simply treating T-scores."[47]

History

Osteopenia, from Greek ὀστέον (ostéon), "bone" and πενία (penía), "poverty", is a condition of sub-normally mineralized bone, usually the result of a rate of bone lysis that exceeds the rate of bone matrix synthesis. See also osteoporosis.

In June 1992, the World Health Organization defined osteopenia.[48][34] An osteoporosis epidemiologist at the Mayo Clinic who participated in setting the criterion in 1992 said "It was just meant to indicate the emergence of a problem", and noted that "It didn't have any particular diagnostic or therapeutic significance. It was just meant to show a huge group who looked like they might be at risk."[49]

See also

References

  1. ↑ staff, familydoctor org editorial. "What Is Osteopenia?" (in en-US). https://familydoctor.org/condition/osteopenia/. 
  2. ↑ "Low bone mineral density and fracture burden in postmenopausal women". CMAJ 177 (6): 575–80. September 2007. doi:10.1503/cmaj.070234. PMID 17846439. 
  3. ↑ "The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine". Journal of Bone and Mineral Research 29 (11): 2520–6. November 2014. doi:10.1002/jbmr.2269. PMID 24771492. 
  4. ↑ staff, familydoctor org editorial. "What Is Osteopenia? – Osteoporosis" (in en-US). https://familydoctor.org/condition/osteopenia/. 
  5. ↑ "Who's at risk? | International Osteoporosis Foundation". https://www.iofbonehealth.org/whos-risk. 
  6. ↑ 6.0 6.1 Karaguzel, Gulay; Holick, Michael F. (December 2010). "Diagnosis and treatment of osteopenia" (in en). Reviews in Endocrine and Metabolic Disorders 11 (4): 237–251. doi:10.1007/s11154-010-9154-0. ISSN 1389-9155. PMID 21234807. 
  7. ↑ "Aging and bone loss: new insights for the clinician". Therapeutic Advances in Musculoskeletal Disease 4 (2): 61–76. April 2012. doi:10.1177/1759720X11430858. PMID 22870496. 
  8. ↑ Varacallo, Matthew; Seaman, Travis J.; Jandu, Jagmohan S.; Pizzutillo, Peter (2021), "Osteopenia", StatPearls (Treasure Island (FL): StatPearls Publishing), PMID 29763053, http://www.ncbi.nlm.nih.gov/books/NBK499878/, retrieved 2021-03-12 
  9. ↑ "Bone mineral density in adolescent female athletes: relationship to exercise type and muscle strength". Medicine and Science in Sports and Exercise 34 (2): 286–94. February 2002. doi:10.1097/00005768-200202000-00017. PMID 11828239. https://researchbank.acu.edu.au/cgi/viewcontent.cgi?article=6637&context=fhs_pub. 
  10. ↑ "American College of Sports Medicine Position Stand: physical activity and bone health". Medicine and Science in Sports and Exercise 36 (11): 1985–96. November 2004. doi:10.1249/01.mss.0000142662.21767.58. PMID 15514517. 
  11. ↑ "Participation in road cycling vs running is associated with lower bone mineral density in men". Metabolism 57 (2): 226–32. February 2008. doi:10.1016/j.metabol.2007.09.005. PMID 18191053. 
  12. ↑ "The female athlete triad: an emerging role for physical therapy". The Journal of Orthopaedic and Sports Physical Therapy 33 (10): 594–614. October 2003. doi:10.2519/jospt.2003.33.10.594. PMID 14620789. 
  13. ↑ "Bone mineral affection in asymptomatic adult patients with celiac disease". The American Journal of Gastroenterology 89 (12): 2130–4. December 1994. PMID 7977227. 
  14. ↑ "Celiac Disease and Its Role in the Development of Metabolic Bone Disease". Journal of Clinical Densitometry 23 (2): 190–199. July 2019. doi:10.1016/j.jocd.2019.06.005. PMID 31320223. 
  15. ↑ Delitala, Alessandro P.; Scuteri, Angelo; Doria, Carlo (2020-04-06). "Thyroid Hormone Diseases and Osteoporosis". Journal of Clinical Medicine 9 (4): 1034. doi:10.3390/jcm9041034. ISSN 2077-0383. PMID 32268542. 
  16. ↑ "Anorexia Nervosa and Its Impact on Bone Health" (in en-US). 2018-02-28. https://www.edcatalogue.com/anorexia-nervosa-impact-bone-health/. 
  17. ↑ "Glucocorticoid-induced Osteoperosis". https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Glucocorticoid-induced-Osteoperosis. 
  18. ↑ 18.0 18.1 18.2 "2019 ISCD Official Positions – Adult – International Society for Clinical Densitometry (ISCD)" (in en-US). https://www.iscd.org/official-positions/2019-iscd-official-positions-adult/. 
  19. ↑ "Enhanced precision with dual-energy X-ray absorptiometry". Calcified Tissue International 51 (1): 14–7. July 1992. doi:10.1007/bf00296209. PMID 1393769. 
  20. ↑ "Radiation exposure in bone mineral density assessment". Applied Radiation and Isotopes 50 (1): 215–36. January 1999. doi:10.1016/s0969-8043(98)00026-8. PMID 10028639. 
  21. ↑ "Final Update Summary: Osteoporosis to Prevent Fractures: Screening – US Preventive Services Task Force". https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/osteoporosis-screening1. 
  22. ↑ "Bone Density Test, Osteoporosis Screening & T-score Interpretation" (in en-US). https://www.nof.org/patients/diagnosis-information/bone-density-examtesting/. 
  23. ↑ "Bone Density Scan: MedlinePlus Medical Test" (in en). https://medlineplus.gov/lab-tests/bone-density-scan/. 
  24. ↑ Prevention and management of osteoporosis : report of a WHO scientific group. WHO technical report series. 921. World Health Organization. 2003. 1-164, back cover. ISBN 978-9241209212. https://iris.who.int/handle/10665/42841. 
  25. ↑ "Fracture Risk Assessment Tool". World Health Organization. http://www.shef.ac.uk/FRAX/index.htm. 
  26. ↑ "UpToDate". https://www.uptodate.com/contents/overview-of-dual-energy-x-ray-absorptiometry. 
  27. ↑ "UpToDate". https://www.uptodate.com/contents/prevention-of-osteoporosis. 
  28. ↑ "Menopause & Osteoporosis" (in en). https://my.clevelandclinic.org/health/articles/10091-menopause--osteoporosis. 
  29. ↑ 29.0 29.1 "Osteoporosis Overview | NIH Osteoporosis and Related Bone Diseases National Resource Center". https://www.bones.nih.gov/health-info/bone/osteoporosis/overview#Prevention. 
  30. ↑ "Preventing Osteoporosis". International Osteoporosis Foundation. https://www.iofbonehealth.org/preventing-osteoporosis. 
  31. ↑ "Diseases and Conditions Osteoporosis". https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Osteoporosis. 
  32. ↑ Howe, T. E.; Shea, B.; Dawson, L. J.; Downie, F.; Murray, A.; Ross, C.; Harbour, R. T.; Caldwell, L. M. et al. (2011). "Exercise for preventing and treating osteoporosis in postmenopausal women". The Cochrane Database of Systematic Reviews (7): CD000333. doi:10.1002/14651858.CD000333.pub2. PMID 21735380. https://pubmed.ncbi.nlm.nih.gov/21735380/. Retrieved 2020-10-27. 
  33. ↑ Murphy, Kate (2009-09-07). "New Osteoporosis Diagnostic Tool Draws Criticism" (in en-US). The New York Times. ISSN 0362-4331. https://www.nytimes.com/2009/09/08/health/08bone.html. 
  34. ↑ 34.0 34.1 "How A Bone Disease Grew To Fit The Prescription" (in en). https://www.npr.org/2009/12/21/121609815/how-a-bone-disease-grew-to-fit-the-prescription. 
  35. ↑ "One Minute Consult | What is osteopenia, and what should be done about it?". https://www.clevelandclinicmeded.com/medicalpubs/ccjm/Jan06/watts.htm. 
  36. ↑ "Osteopenia Warrants Treatment—Selectively—to Reduce Fracture Risk" (in en). https://www.endocrineweb.com/professional/osteoporosis/osteopenia-warrants-selective-treatment-to-reduce-fracture-risk. 
  37. ↑ "FRAX — WHO Fracture Risk Assessment Tool". World Health Organization. http://www.shef.ac.uk/FRAX/. 
  38. ↑ Unnanuntana, Aasis; Gladnick, Brian P; Donnelly, Eve; Lane, Joseph M (March 2010). "The Assessment of Fracture Risk" (in en). The Journal of Bone and Joint Surgery. American Volume 92 (3): 743–753. doi:10.2106/JBJS.I.00919. ISSN 0021-9355. PMID 20194335. 
  39. ↑ "Fracture Risk Assessment Tool". https://www.sheffield.ac.uk/FRAX/tool.aspx?country=23. 
  40. ↑ Cosman, F.; de Beur, S. J.; LeBoff, M. S.; Lewiecki, E. M.; Tanner, B.; Randall, S.; Lindsay, R. (October 2014). "Clinician's Guide to Prevention and Treatment of Osteoporosis" (in en). Osteoporosis International 25 (10): 2359–2381. doi:10.1007/s00198-014-2794-2. ISSN 0937-941X. PMID 25182228. 
  41. ↑ Camacho, Pauline M.; Petak, Steven M.; Binkley, Neil; Clarke, Bart L.; Harris, Steven T.; Hurley, Daniel L.; Kleerekoper, Michael; Lewiecki, E. Michael et al. (September 2016). "American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary" (in en). Endocrine Practice 22 (9): 1111–1118. doi:10.4158/EP161435.ESGL. ISSN 1530-891X. PMID 27643923. 
  42. ↑ Qaseem, Amir; Forciea, Mary Ann; McLean, Robert M.; Denberg, Thomas D.; for the Clinical Guidelines Committee of the American College of Physicians (2017-06-06). "Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians" (in en). Annals of Internal Medicine 166 (11): 818–839. doi:10.7326/M15-1361. ISSN 0003-4819. PMID 28492856. 
  43. ↑ Iqbal, Shumaila M; Qamar, Iqra; Zhi, Cassandra; Nida, Anum; Aslam, Hafiz M (2019-02-27). "Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review" (in en). Cureus 11 (2): e4146. doi:10.7759/cureus.4146. ISSN 2168-8184. PMID 31058029. 
  44. ↑ "Clinical practice. Postmenopausal osteoporosis". The New England Journal of Medicine 353 (6): 595–603. August 2005. doi:10.1056/NEJMcp043801. PMID 16093468. 
  45. ↑ Editorial Staff (2018-01-30). "Rethinking Drug Treatment for Osteopenia" (in en-US). https://www.healthandwellnessalerts.berkeley.edu/topics/rethinking-drug-treatment-for-osteopenia/. 
  46. ↑ "Drugs for pre-osteoporosis: prevention or disease mongering?". BMJ 336 (7636): 126–9. January 2008. doi:10.1136/bmj.39435.656250.AD. PMID 18202066. 
  47. ↑ McClung, Michael R. (2005-05-03). "Osteopenia: To Treat or Not To Treat?" (in en). Annals of Internal Medicine 142 (9): 796–7. doi:10.7326/0003-4819-142-9-200505030-00018. ISSN 0003-4819. PMID 15867413. 
  48. ↑ says, Albino Llaza (2010-04-12). "What is Osteopenia?" (in en). https://www.news-medical.net/health/What-is-Osteopenia.aspx. 
  49. ↑ Kolata, Gina (September 28, 2003). "Bone Diagnosis Gives New Data But No Answers". New York Times. https://query.nytimes.com/gst/fullpage.html?res=9C07E7DA103DF93BA1575AC0A9659C8B63&sec=&spon=. 

External links

Classification



Retrieved from "https://handwiki.org/wiki/index.php?title=Unsolved:Osteopenia&oldid=3263897"